These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

541 related items for PubMed ID: 22733891

  • 21. Comparison of Dynamic Phase Enhancement of Hepatocellular Carcinoma Using Gadoxetate Disodium vs Gadobenate Dimeglumine.
    Tirkes T, Mehta P, Aisen AM, Lall C, Akisik F.
    J Comput Assist Tomogr; 2015; 39(4):479-82. PubMed ID: 25783800
    [Abstract] [Full Text] [Related]

  • 22. Contrast-enhanced MR mammography: improved lesion detection and differentiation with gadobenate dimeglumine.
    Pediconi F, Catalano C, Padula S, Roselli A, Dominelli V, Cagioli S, Kirchin MA, Pirovano G, Passariello R.
    AJR Am J Roentgenol; 2008 Nov; 191(5):1339-46. PubMed ID: 18941066
    [Abstract] [Full Text] [Related]

  • 23. Focal fat deposition at liver MRI with gadobenate dimeglumine and gadoxetic acid: Quantitative and qualitative analysis.
    Yeom SK, Byun JH, Kim HJ, Park SH, Kim N, Shin YM, Kim PN.
    Magn Reson Imaging; 2013 Jul; 31(6):911-7. PubMed ID: 23598063
    [Abstract] [Full Text] [Related]

  • 24. Gadobenate dimeglumine-enhanced MRI of the breast: analysis of dose response and comparison with gadopentetate dimeglumine.
    Knopp MV, Bourne MW, Sardanelli F, Wasser MN, Bonomo L, Boetes C, Müller-Schimpfle M, Hall-Craggs MA, Hamm B, Orlacchio A, Bartolozzi C, Kessler M, Fischer U, Schneider G, Oudkerk M, Teh WL, Gehl HB, Salerio I, Pirovano G, La Noce A, Kirchin MA, Spinazzi A.
    AJR Am J Roentgenol; 2003 Sep; 181(3):663-76. PubMed ID: 12933457
    [Abstract] [Full Text] [Related]

  • 25. Hepatic enhancement in cirrhosis in the portal venous phase: what are the differences between gadoxetate disodium and gadobenate dimeglumine?
    Vernuccio F, Cannella R, Gozzo C, Greco V, Midiri M, Furlan A, Tang A, Brancatelli G.
    Abdom Radiol (NY); 2020 Aug; 45(8):2409-2417. PubMed ID: 32435849
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Hepatocellular MR contrast agents: enhancement characteristics of liver parenchyma and portal vein after administration of gadoxetic acid in comparison to gadobenate dimeglumine.
    Feuerlein S, Gupta RT, Boll DT, Merkle EM.
    Eur J Radiol; 2012 Sep; 81(9):2037-41. PubMed ID: 21719224
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine.
    Knopp MV, Runge VM, Essig M, Hartman M, Jansen O, Kirchin MA, Moeller A, Seeberg AH, Lodemann KP.
    Radiology; 2004 Jan; 230(1):55-64. PubMed ID: 14695387
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Arterial enhancing-only nodules less than 2 cm in diameter in patients with liver cirrhosis: predictors of hepatocellular carcinoma diagnosis on gadobenate dimeglumine-enhanced MR imaging.
    Quaia E, Pizzolato R, De Paoli L, Angileri R, Ukmar M, Cova MA.
    J Magn Reson Imaging; 2013 Apr; 37(4):892-902. PubMed ID: 23097278
    [Abstract] [Full Text] [Related]

  • 35. Gadoxetate disodium-enhanced hepatic MRI: dose-dependent contrast dynamics of hepatic parenchyma and portal vein.
    Feuerlein S, Boll DT, Gupta RT, Ringe KI, Marin D, Merkle EM.
    AJR Am J Roentgenol; 2011 Jan; 196(1):W18-24. PubMed ID: 21178026
    [Abstract] [Full Text] [Related]

  • 36. Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media: a comparison of gadoxetic acid and gadobenate dimeglumine.
    Filippone A, Blakeborough A, Breuer J, Grazioli L, Gschwend S, Hammerstingl R, Heinz-Peer G, Kittner T, Laghi A, Leen E, Lencioni R, Lucidarme O, Remplik P, Robinson PJ, Ruehm SG, Schaefer F, Stoupis C, Tombach B, Valette PJ, Zech CJ, Huppertz A.
    J Magn Reson Imaging; 2010 Feb; 31(2):356-64. PubMed ID: 20099349
    [Abstract] [Full Text] [Related]

  • 37. Assessment of nonischemic fibrosis in hypertrophic cardiomyopathy: comparison of gadopentetate dimeglumine and gadobenate dimeglumine for enhanced cardiovascular magnetic resonance imaging.
    Rudolph A, von Knobelsdorff-Brenkenhoff F, Wassmuth R, Prothmann M, Utz W, Schulz-Menger J.
    J Magn Reson Imaging; 2014 May; 39(5):1153-60. PubMed ID: 24151119
    [Abstract] [Full Text] [Related]

  • 38. Hyperintense lesions on gadoxetate disodium-enhanced hepatobiliary phase imaging.
    Kim MJ, Rhee HJ, Jeong HT.
    AJR Am J Roentgenol; 2012 Nov; 199(5):W575-86. PubMed ID: 23096201
    [Abstract] [Full Text] [Related]

  • 39. [Gd-EOB-DTPA-enhanced magnetic resonance imaging: differentiation between focal nodular hyperplasia and hepatocellular adenoma].
    Portilha MA, Pedro MT, Ruivo C, Semedo LC, Marques C, Alves FC.
    Acta Med Port; 2011 Dec; 24 Suppl 2():531-8. PubMed ID: 22849944
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.